Search results
Results from the WOW.Com Content Network
For the efficacy estimand, the mean change in weight at week 72 with tirzepatide was −16.0% (95% CI, −16.8 to −15.2), a weight reduction of 16.1 kg (35.5 lb), with the 5-mg dose; −21.4% ...
Tirzepatide works for weight loss by decreasing appetite and slowing the movement of food from the stomach into the small intestine, which may make you feel full more quickly and for a longer period of time. Tirzepatide is a once-weekly injection given under the skin using a pen (autoinjector).
The FDA approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition, for use in addition to a reduced...
Tirzepatide treatment could lead to remarkable and sustained weight loss that is well-tolerated and safe, representing a novel and valuable therapeutic strategy for long-term weight management. Keywords: Weight loss, Tirzepatide, Placebo, Systematic review, Meta-analysis
After losing at least 5% of body weight after 12 weeks of diet and exercise, patients who took the dual glucagon-like peptide 1 and gastric inhibitory polypeptide receptor agonist tirzepatide lost an additional 18.4% of weight, according to results from the phase 3 SURMOUNT-3 trial.
While tirzepatide produces greater weight loss than semaglutide in patients with T2D, 11 data from head-to-head trials comparing these therapies in patients with overweight or obesity are not yet available.
Overall, 300 participants (89.5%) receiving tirzepatide at 88 weeks maintained at least 80% of the weight loss during the lead-in period compared with 16.6% receiving placebo (P < .001). The overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide and 9.9% for placebo.
Recent studies suggest that tirzepatide, a dual glucose-dependent insulinotropic-peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has significant weight loss effects.
Key end points were the percent change in body weight from baseline to week 176 and onset of T2DM during the 176-week and 193-week periods. At 176 weeks, the mean percent change in body weight among the groups was as follows (P < 0.001 for all comparisons with placebo): tirzepatide 5 mg: -12.3% ; tirzepatide 10 mg: -18.7% ; tirzepatide 15 mg ...
All tirzepatide doses induced statistically significantly more weight loss than placebo, in a dose-dependent manner. At the trial end, 85%, 89% and 91% of participants in the tirzepatide 5...